Literature DB >> 24196990

Thrombocytopenia and thrombosis: a double-edged sword.

Myat Tun Lin Nyo1, Asgar Ali Kalla.   

Abstract

Severe thrombocytopenia with bleeding associated with a life-threatening thrombotic manifestation in the setting of antiphospholipid syndrome is a major diagnostic and therapeutic challenge for the clinician. Hemorrhage is a less common complication than thrombosis in patients with APS, although severe thrombocytopenia can sometimes result in bleeding. There are no evidence-based guidelines regarding the management of a patient with severe thrombocytopenia associated with a major thrombotic manifestation. In this case report, we review the literature reporting the difficulties in management of such patient.

Entities:  

Mesh:

Year:  2013        PMID: 24196990     DOI: 10.1007/s10067-013-2416-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Management of patients with refractory immune thrombocytopenic purpura.

Authors:  J N George
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'.

Authors:  R Cervera
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study.

Authors:  Lucía Comellas-Kirkerup; Gabriela Hernández-Molina; Antonio R Cabral
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

Review 5.  Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies.

Authors:  Cloé Comarmond; Patrice Cacoub
Journal:  Autoimmun Rev       Date:  2012-12-30       Impact factor: 9.754

6.  Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura.

Authors:  Arwa Z Al-Riyami; James Lee; Mary Connolly; Evan Shereck
Journal:  Pediatr Blood Cancer       Date:  2011-03-28       Impact factor: 3.167

7.  EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.

Authors:  K Einhäupl; J Stam; M-G Bousser; S F T M De Bruijn; J M Ferro; I Martinelli; F Masuhr
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

Review 8.  Antiphospholipid syndrome.

Authors:  Guillermo Ruiz-Irastorza; Mark Crowther; Ware Branch; Munther A Khamashta
Journal:  Lancet       Date:  2010-09-06       Impact factor: 79.321

9.  Belimumab for systemic lupus erythematosus: a practice-based view.

Authors:  I Parodis; M Axelsson; I Gunnarsson
Journal:  Lupus       Date:  2013-04       Impact factor: 2.911

10.  Cerebral venous thrombosis after immune thrombocytopenic purpura and anti-D immune globulin therapy.

Authors:  Husam R Kayyali; Ahmed T Abdelmoity; M Craig Morriss; William D Graf
Journal:  J Child Neurol       Date:  2008-01-09       Impact factor: 1.987

View more
  1 in total

1.  Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature.

Authors:  Alba Jerez-Lienas; Alexis Mathian; Jenifer Aboab; Isabelle Crassard; Miguel Hie; Fleur Cohen-Aubart; Julien Haroche; Denis Wahl; Ricard Cervera; Zahir Amoura
Journal:  Brain Sci       Date:  2021-12-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.